Abstract
Summary
The global market for Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs was estimated to be worth US$ million in 2023 and is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs by region & country, by Type, and by Application.
The Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs.
Market Segmentation
By Company
Roche
Regeneron Pharmaceuticals
Bayer
Santen Oy
Kanghong Pharmaceuticals
Novartis
Eli Lilly and Company
TRACON Pharmaceuticals
Pfizer
GSK
BIOCAD
Segment by Type:
Agonist
Allosteric Modulator
Kinase Inhibitor
Monoclonal Antibody
Others
Segment by Application
Hospital
Clinic
Others
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs manufacturers competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Revenue of Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Revenue of Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs by region & country, by Type, and by Application.
The Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs.
Market Segmentation
By Company
Roche
Regeneron Pharmaceuticals
Bayer
Santen Oy
Kanghong Pharmaceuticals
Novartis
Eli Lilly and Company
TRACON Pharmaceuticals
Pfizer
GSK
BIOCAD
Segment by Type:
Agonist
Allosteric Modulator
Kinase Inhibitor
Monoclonal Antibody
Others
Segment by Application
Hospital
Clinic
Others
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs manufacturers competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Revenue of Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Revenue of Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.
Table of Contents
1 Market Overview
1.1 Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Product Introduction
1.2 Global Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Market Size Forecast
1.3 Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Market Trends & Drivers
1.3.1 Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Industry Trends
1.3.2 Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Market Drivers & Opportunity
1.3.3 Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Market Challenges
1.3.4 Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Market Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Players Revenue Ranking (2023)
2.2 Global Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Revenue by Company (2019-2024)
2.3 Key Companies Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Manufacturing Base Distribution and Headquarters
2.4 Key Companies Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Product Offered
2.5 Key Companies Time to Begin Mass Production of Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs
2.6 Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Market Competitive Analysis
2.6.1 Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Market Concentration Rate (2019-2024)
2.6.2 Global 5 and 10 Largest Companies by Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Revenue in 2023
2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs as of 2023)
2.7 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 Agonist
3.1.2 Allosteric Modulator
3.1.3 Kinase Inhibitor
3.1.4 Monoclonal Antibody
3.1.5 Others
3.2 Global Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Sales Value by Type
3.2.1 Global Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Sales Value by Type (2019 VS 2023 VS 2030)
3.2.2 Global Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Sales Value, by Type (2019-2030)
3.2.3 Global Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Sales Value, by Type (%) (2019-2030)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 Hospital
4.1.2 Clinic
4.1.3 Others
4.2 Global Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Sales Value by Application
4.2.1 Global Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Sales Value by Application (2019 VS 2023 VS 2030)
4.2.2 Global Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Sales Value, by Application (2019-2030)
4.2.3 Global Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Sales Value, by Application (%) (2019-2030)
5 Segmentation by Region
5.1 Global Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Sales Value by Region
5.1.1 Global Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Sales Value by Region: 2019 VS 2023 VS 2030
5.1.2 Global Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Sales Value by Region (2019-2024)
5.1.3 Global Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Sales Value by Region (2025-2030)
5.1.4 Global Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Sales Value by Region (%), (2019-2030)
5.2 North America
5.2.1 North America Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Sales Value, 2019-2030
5.2.2 North America Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Sales Value by Country (%), 2023 VS 2030
5.3 Europe
5.3.1 Europe Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Sales Value, 2019-2030
5.3.2 Europe Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Sales Value by Country (%), 2023 VS 2030
5.4 Asia Pacific
5.4.1 Asia Pacific Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Sales Value, 2019-2030
5.4.2 Asia Pacific Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Sales Value by Country (%), 2023 VS 2030
5.5 South America
5.5.1 South America Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Sales Value, 2019-2030
5.5.2 South America Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Sales Value by Country (%), 2023 VS 2030
5.6 Middle East & Africa
5.6.1 Middle East & Africa Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Sales Value, 2019-2030
5.6.2 Middle East & Africa Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Sales Value by Country (%), 2023 VS 2030
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Sales Value Growth Trends, 2019 VS 2023 VS 2030
6.2 Key Countries/Regions Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Sales Value
6.3 United States
6.3.1 United States Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Sales Value, 2019-2030
6.3.2 United States Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Sales Value by Type (%), 2023 VS 2030
6.3.3 United States Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Sales Value by Application, 2023 VS 2030
6.4 Europe
6.4.1 Europe Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Sales Value, 2019-2030
6.4.2 Europe Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Sales Value by Type (%), 2023 VS 2030
6.4.3 Europe Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Sales Value by Application, 2023 VS 2030
6.5 China
6.5.1 China Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Sales Value, 2019-2030
6.5.2 China Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Sales Value by Type (%), 2023 VS 2030
6.5.3 China Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Sales Value by Application, 2023 VS 2030
6.6 Japan
6.6.1 Japan Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Sales Value, 2019-2030
6.6.2 Japan Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Sales Value by Type (%), 2023 VS 2030
6.6.3 Japan Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Sales Value by Application, 2023 VS 2030
6.7 South Korea
6.7.1 South Korea Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Sales Value, 2019-2030
6.7.2 South Korea Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Sales Value by Type (%), 2023 VS 2030
6.7.3 South Korea Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Sales Value by Application, 2023 VS 2030
6.8 Southeast Asia
6.8.1 Southeast Asia Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Sales Value, 2019-2030
6.8.2 Southeast Asia Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Sales Value by Type (%), 2023 VS 2030
6.8.3 Southeast Asia Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Sales Value by Application, 2023 VS 2030
6.9 India
6.9.1 India Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Sales Value, 2019-2030
6.9.2 India Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Sales Value by Type (%), 2023 VS 2030
6.9.3 India Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Sales Value by Application, 2023 VS 2030
7 Company Profiles
7.1 Roche
7.1.1 Roche Profile
7.1.2 Roche Main Business
7.1.3 Roche Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Products, Services and Solutions
7.1.4 Roche Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Revenue (US$ Million) & (2019-2024)
7.1.5 Roche Recent Developments
7.2 Regeneron Pharmaceuticals
7.2.1 Regeneron Pharmaceuticals Profile
7.2.2 Regeneron Pharmaceuticals Main Business
7.2.3 Regeneron Pharmaceuticals Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Products, Services and Solutions
7.2.4 Regeneron Pharmaceuticals Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Revenue (US$ Million) & (2019-2024)
7.2.5 Regeneron Pharmaceuticals Recent Developments
7.3 Bayer
7.3.1 Bayer Profile
7.3.2 Bayer Main Business
7.3.3 Bayer Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Products, Services and Solutions
7.3.4 Bayer Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Revenue (US$ Million) & (2019-2024)
7.3.5 Santen Oy Recent Developments
7.4 Santen Oy
7.4.1 Santen Oy Profile
7.4.2 Santen Oy Main Business
7.4.3 Santen Oy Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Products, Services and Solutions
7.4.4 Santen Oy Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Revenue (US$ Million) & (2019-2024)
7.4.5 Santen Oy Recent Developments
7.5 Kanghong Pharmaceuticals
7.5.1 Kanghong Pharmaceuticals Profile
7.5.2 Kanghong Pharmaceuticals Main Business
7.5.3 Kanghong Pharmaceuticals Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Products, Services and Solutions
7.5.4 Kanghong Pharmaceuticals Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Revenue (US$ Million) & (2019-2024)
7.5.5 Kanghong Pharmaceuticals Recent Developments
7.6 Novartis
7.6.1 Novartis Profile
7.6.2 Novartis Main Business
7.6.3 Novartis Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Products, Services and Solutions
7.6.4 Novartis Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Revenue (US$ Million) & (2019-2024)
7.6.5 Novartis Recent Developments
7.7 Eli Lilly and Company
7.7.1 Eli Lilly and Company Profile
7.7.2 Eli Lilly and Company Main Business
7.7.3 Eli Lilly and Company Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Products, Services and Solutions
7.7.4 Eli Lilly and Company Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Revenue (US$ Million) & (2019-2024)
7.7.5 Eli Lilly and Company Recent Developments
7.8 TRACON Pharmaceuticals
7.8.1 TRACON Pharmaceuticals Profile
7.8.2 TRACON Pharmaceuticals Main Business
7.8.3 TRACON Pharmaceuticals Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Products, Services and Solutions
7.8.4 TRACON Pharmaceuticals Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Revenue (US$ Million) & (2019-2024)
7.8.5 TRACON Pharmaceuticals Recent Developments
7.9 Pfizer
7.9.1 Pfizer Profile
7.9.2 Pfizer Main Business
7.9.3 Pfizer Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Products, Services and Solutions
7.9.4 Pfizer Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Revenue (US$ Million) & (2019-2024)
7.9.5 Pfizer Recent Developments
7.10 GSK
7.10.1 GSK Profile
7.10.2 GSK Main Business
7.10.3 GSK Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Products, Services and Solutions
7.10.4 GSK Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Revenue (US$ Million) & (2019-2024)
7.10.5 GSK Recent Developments
7.11 BIOCAD
7.11.1 BIOCAD Profile
7.11.2 BIOCAD Main Business
7.11.3 BIOCAD Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Products, Services and Solutions
7.11.4 BIOCAD Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Revenue (US$ Million) & (2019-2024)
7.11.5 BIOCAD Recent Developments
8 Industry Chain Analysis
8.1 Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Industrial Chain
8.2 Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Sales Model
8.5.2 Sales Channel
8.5.3 Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.2 Data Source
10.2 Author Details
10.3 Disclaimer